COVID-19 Vaccine Schedule

COVID-19 vaccines available in Alberta for 2024-2025:

- Moderna Spikevax KP.2 COVID-19 vaccine (6 months of age and older)
- Pfizer-BioNTech KP.2 COVID-19 vaccine (12 years of age and older)

TABLE 1: KP.2 DOSES FOR INDIVIDUALS WHO ARE NOT IMMUNOCOMPROMISED

| Age Group | COVID-19 Immunization History | Recommended KP.2 COVID-19 vaccine doses | FIRST dose of KP.2 COVID- 19 vaccine | SECOND dose of KP.2 COVID- 19 vaccine |
|--------------------|----------------------------------|---|---|--|
| 5 years of age and | Received 1 or more previous non- | 1 | At least 3 months from | |
| older | KP.2 doses | | previous non-KP.2 dose | |
| | Unimmunized | 1 | As soon as you can | |
| 6 months to 4 | Received 2 or more previous non- | 1 | At least 3 months from | |
| years of age | KP.2 doses | | previous non-KP.2 dose | |
| | Received 1 previous non-KP.2 | 1 | 8 weeks from last non-KP.2 | |
| | dose | | dose | |
| | Unimmunized | 2 | As soon as you can | 8 weeks from FIRST dose |

Notes

- COVID-19 immunization history refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or XBB.1.5 Moderna or Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine not approved by Health Canada, please call Health Link (811).
- Vaccine after infection: It is recommended that the COVID-19 vaccine be delayed for those who have tested positive for COVID-19 (by PCR or rapid antigen test). See <u>Table 3</u> below for more details. If you have questions, please call Health Link (811), or ask your healthcare provider.

TABLE 2: KP.2 DOSES FOR INDIVIDUALS WHO ARE IMMUNOCOMPROMISED

Immunocompromised individuals should follow the schedule below and receive the appropriate number of KP.2 COVID-19 vaccine to complete a three-dose COVID-19 vaccine series. Regardless of whether they have received one or two non-KP.2 COVID-19 vaccine doses, the previous dose(s) should be counted, and the series should not be restarted.

| Age Group | COVID-19 Immunization History | Recommended KP.2 COVID-19 vaccine doses | FIRST dose of KP.2 COVID-19 vaccine | SECOND dose of KP.2 COVID- 19 vaccine | THIRD dose of KP.2 COVID-19 vaccine |
|---------------------|---|---|--|--|---|
| 6 months of age and | Received 3 or more previous doses of non-KP.2 vaccine doses | 1 | At least 3 months from previous non-KP.2 dose | | |
| older | Received 2 previous doses of non-KP.2 vaccine doses | 1 | 8 weeks from last non-KP.2 dose* | | |
| | Received 1 previous dose of non- KP.2 vaccine dose | 2 | 4 weeks from previous non- KP.2 COVID-19 vaccine dose | 8 weeks from previous non-KP.2 COVID-19 vaccine dose* | |
| | Unimmunized | 3 | As soon as you can | 4 weeks after FIRST dose of KP.2 COVID-19 vaccine | 8 weeks after SECOND dose of KP.2 COVID-19 vaccine* |

^{*}A 4-week interval may be considered.

Notes

- A list of eligible immunocompromising conditions can be found here.
- COVID-19 vaccines available in Alberta for 2024-2025:
 - Moderna Spikevax KP.2 COVID-19 vaccine (6 months of age and older)
 - Pfizer-BioNTech KP.2 COVID-19 vaccine (12 years of age and older)
- COVID-19 immunization history refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or XBB.1.5 Moderna, Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine that is not approved by Health Canada, please call Health Link (811).
- Hematopoietic stem cell transplants recipients pre-transplant and post-transplant while in immunosuppressed state and individuals receiving Chimeric Antigen Receptor T-Cell Therapy (CAR T-cell therapy), please see:
 - Principles of Immunization in Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients
 - Child HSCT
 - Adult HSCT
- Vaccine after infection: It is recommended that the COVID-19 vaccine be delayed for those who have tested positive for COVID-19 (by PCR or rapid antigen test). See <u>Table 3</u> below for more details. If you have questions, please call Health Link (811), or ask your healthcare provider.

COVID-19 Vaccine Schedule

TABLE 3: KP.2 DOSES - SPACING POST-INFECTION

| NOT IMMUNOCOMPROMISED | | | | | |
|-----------------------|------------------------------|--|--|--|--|
| Age group | Vaccine history | Interval between dose and positive COVID-19 test | | | |
| 5 years and older | Any | 3 months | | | |
| 6 months to 4 years | Two or more previous doses | 3 months | | | |
| | One previous dose | 8 weeks | | | |
| | Unimmunized | 8 weeks | | | |
| IMMUNOCOMPROMISED | | | | | |
| Age group | Vaccine history | Interval between dose and positive COVID-19 test | | | |
| 6 months and older | Three or more previous doses | 3 months | | | |
| | One or two previous doses | 4 – 8 weeks | | | |
| | Unimmunized | 4 – 8 weeks | | | |

Notes

• For individuals with a history of multisystem inflammatory syndrome in children (MIS-C), please consult your primary care provider.